549 related articles for article (PubMed ID: 31623894)
1. Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial.
CRASH-3 trial collaborators
Lancet; 2019 Nov; 394(10210):1713-1723. PubMed ID: 31623894
[TBL] [Abstract][Full Text] [Related]
2. Tranexamic acid to reduce head injury death in people with traumatic brain injury: the CRASH-3 international RCT.
Roberts I; Shakur-Still H; Aeron-Thomas A; Beaumont D; Belli A; Brenner A; Cargill M; Chaudhri R; Douglas N; Frimley L; Gilliam C; Geer A; Jamal Z; Jooma R; Mansukhani R; Miners A; Pott J; Prowse D; Shokunbi T; Williams J
Health Technol Assess; 2021 Apr; 25(26):1-76. PubMed ID: 33928903
[TBL] [Abstract][Full Text] [Related]
3. CRASH-2 (Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage) intracranial bleeding study: the effect of tranexamic acid in traumatic brain injury--a nested randomised, placebo-controlled trial.
Perel P; Al-Shahi Salman R; Kawahara T; Morris Z; Prieto-Merino D; Roberts I; Sandercock P; Shakur H; Wardlaw J
Health Technol Assess; 2012; 16(13):iii-xii, 1-54. PubMed ID: 22417901
[TBL] [Abstract][Full Text] [Related]
4. The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients.
Roberts I; Shakur H; Coats T; Hunt B; Balogun E; Barnetson L; Cook L; Kawahara T; Perel P; Prieto-Merino D; Ramos M; Cairns J; Guerriero C
Health Technol Assess; 2013 Mar; 17(10):1-79. PubMed ID: 23477634
[TBL] [Abstract][Full Text] [Related]
5. Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial.
HALT-IT Trial Collaborators
Lancet; 2020 Jun; 395(10241):1927-1936. PubMed ID: 32563378
[TBL] [Abstract][Full Text] [Related]
6. A nested mechanistic sub-study into the effect of tranexamic acid versus placebo on intracranial haemorrhage and cerebral ischaemia in isolated traumatic brain injury: study protocol for a randomised controlled trial (CRASH-3 Trial Intracranial Bleeding Mechanistic Sub-Study [CRASH-3 IBMS]).
Mahmood A; Roberts I; Shakur H
Trials; 2017 Jul; 18(1):330. PubMed ID: 28716153
[TBL] [Abstract][Full Text] [Related]
7. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial.
WOMAN Trial Collaborators
Lancet; 2017 May; 389(10084):2105-2116. PubMed ID: 28456509
[TBL] [Abstract][Full Text] [Related]
8. Effect of Out-of-Hospital Tranexamic Acid vs Placebo on 6-Month Functional Neurologic Outcomes in Patients With Moderate or Severe Traumatic Brain Injury.
Rowell SE; Meier EN; McKnight B; Kannas D; May S; Sheehan K; Bulger EM; Idris AH; Christenson J; Morrison LJ; Frascone RJ; Bosarge PL; Colella MR; Johannigman J; Cotton BA; Callum J; McMullan J; Dries DJ; Tibbs B; Richmond NJ; Weisfeldt ML; Tallon JM; Garrett JS; Zielinski MD; Aufderheide TP; Gandhi RR; Schlamp R; Robinson BRH; Jui J; Klein L; Rizoli S; Gamber M; Fleming M; Hwang J; Vincent LE; Williams C; Hendrickson A; Simonson R; Klotz P; Sopko G; Witham W; Ferrara M; Schreiber MA
JAMA; 2020 Sep; 324(10):961-974. PubMed ID: 32897344
[TBL] [Abstract][Full Text] [Related]
9. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
; Roberts I; Shakur H; Afolabi A; Brohi K; Coats T; Dewan Y; Gando S; Guyatt G; Hunt BJ; Morales C; Perel P; Prieto-Merino D; Woolley T
Lancet; 2011 Mar; 377(9771):1096-101, 1101.e1-2. PubMed ID: 21439633
[TBL] [Abstract][Full Text] [Related]
10. Understanding the neuroprotective effect of tranexamic acid: an exploratory analysis of the CRASH-3 randomised trial.
Brenner A; Belli A; Chaudhri R; Coats T; Frimley L; Jamaluddin SF; Jooma R; Mansukhani R; Sandercock P; Shakur-Still H; Shokunbi T; Roberts I;
Crit Care; 2020 Nov; 24(1):560. PubMed ID: 33172504
[TBL] [Abstract][Full Text] [Related]
11. Effect of tranexamic acid on intracranial haemorrhage and infarction in patients with traumatic brain injury: a pre-planned substudy in a sample of CRASH-3 trial patients.
Mahmood A; Needham K; Shakur-Still H; Harris T; Jamaluddin SF; Davies D; Belli A; Mohamed FL; Leech C; Lotfi HM; Moss P; Lecky F; Hopkins P; Wong D; Boyle A; Wilson M; Darwent M; Roberts I
Emerg Med J; 2021 Apr; 38(4):270-278. PubMed ID: 33262252
[TBL] [Abstract][Full Text] [Related]
12. A high-dose 24-hour tranexamic acid infusion for the treatment of significant gastrointestinal bleeding: HALT-IT RCT.
Roberts I; Shakur-Still H; Afolabi A; Akere A; Arribas M; Austin E; Bal K; Bazeer N; Beaumont D; Brenner A; Carrington L; Chaudhri R; Coats T; Gilmore I; Halligan K; Hussain I; Jairath V; Javaid K; Kayani A; Lisman T; Mansukhani R; Miners A; Mutti M; Nadeem MA; Pollok R; Prowse D; Simmons J; Stanworth S; Veitch A; Williams J
Health Technol Assess; 2021 Oct; 25(58):1-86. PubMed ID: 34663491
[TBL] [Abstract][Full Text] [Related]
13. Tranexamic acid for significant traumatic brain injury (The CRASH-3 trial): Statistical analysis plan for an international, randomised, double-blind, placebo-controlled trial.
Roberts I; Belli A; Brenner A; Chaudhri R; Fawole B; Harris T; Jooma R; Mahmood A; Shokunbi T; Shakur H;
Wellcome Open Res; 2018; 3():86. PubMed ID: 30175246
[No Abstract] [Full Text] [Related]
14. CRASH-3 - tranexamic acid for the treatment of significant traumatic brain injury: study protocol for an international randomized, double-blind, placebo-controlled trial.
Dewan Y; Komolafe EO; Mejía-Mantilla JH; Perel P; Roberts I; Shakur H;
Trials; 2012 Jun; 13():87. PubMed ID: 22721545
[TBL] [Abstract][Full Text] [Related]
15. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
; Shakur H; Roberts I; Bautista R; Caballero J; Coats T; Dewan Y; El-Sayed H; Gogichaishvili T; Gupta S; Herrera J; Hunt B; Iribhogbe P; Izurieta M; Khamis H; Komolafe E; Marrero MA; Mejía-Mantilla J; Miranda J; Morales C; Olaomi O; Olldashi F; Perel P; Peto R; Ramana PV; Ravi RR; Yutthakasemsunt S
Lancet; 2010 Jul; 376(9734):23-32. PubMed ID: 20554319
[TBL] [Abstract][Full Text] [Related]
16. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2) A randomised, placebo-controlled trial.
Williams-Johnson JA; McDonald AH; Strachan GG; Williams EW
West Indian Med J; 2010 Dec; 59(6):612-24. PubMed ID: 21702233
[TBL] [Abstract][Full Text] [Related]
17. Tranexamic acid in patients with intracerebral haemorrhage (STOP-AUST): a multicentre, randomised, placebo-controlled, phase 2 trial.
Meretoja A; Yassi N; Wu TY; Churilov L; Sibolt G; Jeng JS; Kleinig T; Spratt NJ; Thijs V; Wijeratne T; Cho DY; Shah D; Cloud GC; Phan T; Bladin C; Moey A; Aviv RI; Barras CD; Sharma G; Hsu CY; Ma H; Campbell BCV; Mitchell P; Yan B; Parsons MW; Tiainen M; Curtze S; Strbian D; Tang SC; Harvey J; Levi C; Donnan GA; Davis SM
Lancet Neurol; 2020 Dec; 19(12):980-987. PubMed ID: 33128912
[TBL] [Abstract][Full Text] [Related]
18. Tranexamic acid is safe to use following mild-to-moderate traumatic brain injury.
Cook R; Lyon-Maris J; Martin R;
BMJ; 2020 Mar; 368():m514. PubMed ID: 32161036
[TBL] [Abstract][Full Text] [Related]
19. Tranexamic acid in traumatic brain injury: an explanatory study nested within the CRASH-3 trial.
CRASH-3 Intracranial Bleeding Mechanistic Study Collaborators
Eur J Trauma Emerg Surg; 2021 Feb; 47(1):261-268. PubMed ID: 32076783
[TBL] [Abstract][Full Text] [Related]
20. Association Between Prehospital Tranexamic Acid Administration and Outcomes of Severe Traumatic Brain Injury.
Bossers SM; Loer SA; Bloemers FW; Den Hartog D; Van Lieshout EMM; Hoogerwerf N; van der Naalt J; Absalom AR; Peerdeman SM; Schwarte LA; Boer C; Schober P;
JAMA Neurol; 2021 Mar; 78(3):338-345. PubMed ID: 33284310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
